TMTPOST — Chinese digital healthcare firm Hangzhou Purui Life Science Technology, which operates globally as PrimeAI, announced on Tuesday that it has completed a Series A funding round worth nearly 100 million yuan ($13.8 million) to expand its artificial intelligence-driven clinical research infrastructure. The round was led by state-backed investment giant CICC Capital, with Sumitomo Corporation Asia Capital and Suzhou Gaoxin Rongsheng participating as co-investors, while China Renaissance acted as the exclusive financial advisor. Management plans to deploy the proceeds to scale the platform's proprietary AI-native clinical trial network, finance corporate acquisitions of traditional clinical research businesses, iterate its artificial intelligence agent clusters, capitalize specialized services, and accelerate its global commercial infrastructure and product delivery footprint. Advanced data modeling and algorithmic infrastructure are becoming increasingly vital to clinical trial networks across the Chinese mainland as pharmaceutical companies look to lower prohibitive research and development expenses. By implementing unified algorithmic workflows to cross-reference electronic medical records with electronic data capture systems, technology-driven clinical providers are progressively shortening standard enrollment cycles and standardizing complex data governance for international regulatory filings.